Program
Capecitabine
Also written as “capecitabine”, “capecitabine [Xeloda]” and “Utidelone in combination with capecitabine”.
Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Stomach Neoplasms · Pancreatic Neoplasms · Neoplasms, led by 13 companies.
Drug pageCapecitabine: every studyMany companies study it; this page follows only the 72 they lead. All 947 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 430 open or running | phase 4since Jul 12, 2004 | May 2, 2000 | none ahead |
| Sanofiits history only | 90 open or running | phase 3since Apr 20, 2004 | Apr 20, 2004 | none ahead |
| R-Pharmits history only | 60 open or running | phase 3since Mar 26, 2004 | Nov 12, 2002 | none ahead |
| Novartisits history only | 41 open or running | phase 3since Jul 26, 2007 | Jul 26, 2007 | Apr 14, 2027phase 2 · NCT06247995 |
| Qilu Pharmaceuticalits history only | 21 open or running | phase 2since Jun 1, 2024 | Feb 10, 2018 | none ahead |
| Academy Military Medical Science, Chinaits history only | 10 open or running | phase 2since Jul 14, 2008 | Jul 14, 2008 | none ahead |
| Bio-Cancer Treatment Internationalits history only | 10 open or running | phase 2since Mar 14, 2014 | Mar 14, 2014 | none ahead |
| EBG MedAustronits history only | 11 open or running | no phasesince May 10, 2021 | May 10, 2021 | Dec 31, 2026NCT04894643 |
| iOMEDICOits history only | 10 open or running | phase 4since Aug 28, 2014 | Aug 28, 2014 | none ahead |
| NovoCureits history only | 10 open or running | no phasesince Feb 20, 2020 | Feb 20, 2020 | none ahead |
| Pharmatech Oncologyits history only | 10 open or running | phase 2since Nov 9, 2001 | Nov 9, 2001 | none ahead |
| Pierre Fabreits history only | 10 open or running | phase 2since Oct 3, 2016 | Oct 3, 2016 | none ahead |
| Prologue Research Internationalits history only | 10 open or running | phase 3since Jun 5, 2003 | Jun 5, 2003 | none ahead |
Also a collaborator on its studies: Exelixis, Clovis Oncology, Johnson & Johnson, Parexel, Baili-Bio (Chengdu) Pharmaceutical, Zai Lab, Chengdu Biostar Pharmaceuticals, Regeneron Pharmaceuticals, GlaxoSmithKline and Yakult Honsha.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Jul 12, 2004.
- Nov 17, 2014Phase 2 study in NeoplasmsNovartis · NCT02294786 · 62 enrolled · Czechia, Israel, Poland and more
- Sep 24, 20152 phase 3 studies in Stomach NeoplasmsHoffmann-La Roche · NCT02560974, NCT02563054
- Sep 30, 2015Phase 2 study in Pancreatic NeoplasmsHoffmann-La Roche · NCT02565641 · 63 enrolled · Korea, Republic of
- Oct 1, 20152 phase 4 studies in Colorectal NeoplasmsHoffmann-La Roche · NCT02567331, NCT02581423
- Oct 14, 2015Phase 2 study in Carcinoma, HepatocellularHoffmann-La Roche · NCT02576964 · 16 enrolled · China, Taiwan, Thailand
- Nov 16, 2015Phase 2 study in Nasopharyngeal NeoplasmsHoffmann-La Roche · NCT02608073 · 45 enrolled · Hong Kong, Indonesia, Malaysia and more
- Feb 25, 2016Phase 2 study in Rectal NeoplasmsHoffmann-La Roche · NCT02694718 · 60 enrolled · Switzerland
- Jul 25, 2016Phase 2 study in Breast NeoplasmsHoffmann-La Roche · NCT02846428 · 182 enrolled · France
- Oct 3, 2016Pierre Fabre’s first study: phase 2 study in Breast NeoplasmsNew to Pierre FabrePierre Fabre · NCT03887130 · 152 enrolled
- Feb 10, 2018Qilu Pharmaceutical’s first study: phase 1 study in Colonic NeoplasmsNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT03435666 · 45 enrolled
- Feb 20, 2020NovoCure’s first study: no phase study in Stomach NeoplasmsNew to NovoCureNovoCure · NCT04281576 · 28 enrolled · Hong Kong
- May 10, 2021EBG MedAustron’s first study: no phase study in Pancreatic NeoplasmsNew to EBG MedAustronEBG MedAustron · NCT04894643 · 10 planned · Austria
- Jan 17, 2024Phase 2 study in Breast NeoplasmsNovartis · NCT06247995 · 20 enrolled · United States, Australia, Canada and more
- Jun 1, 2024Phase 2 study in Advanced Solid TumorQilu Pharmaceutical · NCT06446388 · 360 planned · China
Ahead
- Dec 31, 2026Primary completion: no phase study in Pancreatic NeoplasmsEBG MedAustron · NCT04894643
- Apr 14, 2027Primary completion: phase 2 study in Breast NeoplasmsNovartis · NCT06247995
TargetBeta
“Thymidylate synthase inhibitor; RNA inhibitor”ChEMBL 37, by rule
Other programs on TYMS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pemetrexedrule | Eli Lilly | phase 4 | 141 |
| Fluorouracilrule | Sanofi | phase 4 | 82 |
| Tegafurrule | Otsuka | phase 3 | 25 |
Studies
The newest 60 of 72 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06446388Advanced Solid Tumor · China | 2 | Not yet recruiting | Qilu Pharmaceutical | Jun 30, 2026 | 360 |
| NCT06247995Breast Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Novartis | Apr 14, 2027 | 20 |
| NCT04894643Pancreatic Neoplasms · Austria | – | Recruiting | EBG MedAustron | Dec 31, 2026 | 10 |
| NCT04281576Stomach Neoplasms · Hong Kong | – | Completed | NovoCure | Jun 7, 2024 | 28 |
| NCT03435666Colonic Neoplasms | 1 | UNKNOWN | Qilu Pharmaceutical | Oct 2018 | 45 |
| NCT03887130Breast Neoplasms | 2 | Completed | Pierre Fabre | Apr 18, 2013 | 152 |
| NCT02846428Breast Neoplasms · France | 2 | Completed | Hoffmann-La Roche | Dec 2011 | 182 |
| NCT02694718Rectal Neoplasms · Switzerland | 2 | Completed | Hoffmann-La Roche | Aug 2006 | 60 |
| NCT02608073Nasopharyngeal Neoplasms · Hong Kong, Indonesia, Malaysia and more | 2 | Completed | Hoffmann-La Roche | Nov 2009 | 45 |
| NCT02581423Colorectal Neoplasms · Bulgaria | 4 | Completed | Hoffmann-La Roche | Mar 2007 | 63 |
| NCT02576964Carcinoma, Hepatocellular · China, Taiwan, Thailand | 2 | Completed | Hoffmann-La Roche | Nov 2008 | 16 |
| NCT02567331Colorectal Neoplasms · Bulgaria | 4 | Completed | Hoffmann-La Roche | Apr 2006 | 28 |
| NCT02565641Pancreatic Neoplasms · Korea, Republic of | 2 | Completed | Hoffmann-La Roche | Sep 2006 | 63 |
| NCT02563054Stomach Neoplasms · Argentina, Belize, Brazil and more | 3 | Completed | Hoffmann-La Roche | Aug 2010 | 316 |
| NCT02560974Stomach Neoplasms · China, Korea, Republic of, Taiwan | 3 | Completed | Hoffmann-La Roche | Nov 2012 | 1,035 |
| NCT02294786Neoplasms · Czechia, Israel, Poland and more | 2 | Terminated | Novartis | Oct 19, 2017 | 62 |
| NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more | 2 | Completed | Hoffmann-La Roche | May 31, 2019 | 1,044 |
| NCT02248571Breast Neoplasms · Germany | 4 | Completed | iOMEDICO | Aug 31, 2017 | 85 |
| NCT02089633Carcinoma, Hepatocellular · Hong Kong | 2 | Completed | Bio-Cancer Treatment International | Sep 2016 | 17 |
| NCT02085005Colorectal Cancer Metastatic | 2 | Withdrawn | Sanofi | Aug 2016 | 0 |
| NCT02013830Liver Neoplasms · Australia, Hong Kong, Singapore and more | 2 | Completed | Hoffmann-La Roche | Mar 2008 | 45 |
| NCT01955629Colorectal Cancer Metastatic · Italy | 2 | Terminated | Sanofi | Mar 2015 | 4 |
| NCT01783444Breast Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Novartis | Jul 2, 2018 | 309 |
| NCT01748773Stomach Neoplasms · Turkey | 2 | Completed | Hoffmann-La Roche | Aug 21, 2015 | 34 |
| NCT01450696Stomach Neoplasms · United States, Australia, Bosnia and Herzegovina and more | 3 | Terminated | Hoffmann-La Roche | Feb 2015 | 296 |
| NCT01290718Breast Neoplasms · Taiwan | 2 | Terminated | Hoffmann-La Roche | Dec 2012 | 4 |
| NCT01245582Carcinoma, Hepatocellular | 3 | Withdrawn | Sanofi | Feb 2014 | 0 |
| NCT01227707Colorectal Neoplasms · Italy | 2 | Completed | Hoffmann-La Roche | Aug 2010 | 43 |
| NCT01135498Colorectal Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Apr 2010 | 90 |
| NCT01130337Stomach Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Jun 2014 | 36 |
| NCT01118377Brainstem Glioma · United States | 2 | Completed | Hoffmann-La Roche | Jan 2013 | 45 |
| NCT01077739Colorectal Neoplasms · Belgium | 2 | Completed | Hoffmann-La Roche | Jan 2012 | 75 |
| NCT01077726Breast Neoplasms · France | 2 | Completed | Hoffmann-La Roche | Dec 2010 | 3 |
| NCT00977379Breast Neoplasms · France | 2 | Terminated | Hoffmann-La Roche | Feb 2011 | 24 |
| NCT00929240Breast Neoplasms · Brazil, China, Egypt and more | 3 | Completed | Hoffmann-La Roche | Jun 2014 | 287 |
| NCT00925769Pancreatic Neoplasms · Austria | 1 | Completed | Hoffmann-La Roche | Dec 2013 | 32 |
| NCT00885755Breast Neoplasms · Australia, Spain, Sweden and more | 2 | Completed | Hoffmann-La Roche | Feb 18, 2013 | 33 |
| NCT00811135Breast Neoplasms · Denmark, France, Russian Federation and more | 2 | Completed | Hoffmann-La Roche | Dec 2015 | 88 |
| NCT00796718Colorectal Neoplasms · Slovakia | 2 | Completed | Hoffmann-La Roche | Aug 2010 | 62 |
| NCT00717951Advanced Breast Cancer | 2 | UNKNOWN | Academy Military Medical Science, China | Dec 2009 | 120 |
| NCT00634088Breast Neoplasms · United States, Australia, Italy | 1 | Terminated | R-Pharm | Jun 2010 | 13 |
| NCT00623805Colorectal Neoplasms · Turkey | 3 | Completed | Hoffmann-La Roche | May 2012 | 123 |
| NCT00577031Colorectal Neoplasms · Italy | 4 | Completed | Hoffmann-La Roche | Aug 2011 | 205 |
| NCT00576901Breast Neoplasms · Spain | 2 | Terminated | Hoffmann-La Roche | Jun 2009 | 23 |
| NCT00568022Breast Neoplasms · Japan | 1 | Completed | R-Pharm | Jan 2010 | 9 |
| NCT00532948Glioma · United States | 1 | Completed | Hoffmann-La Roche | Oct 2010 | 24 |
| NCT00508274Breast Neoplasms · China, Hong Kong | 3 | Terminated | Novartis | Dec 2, 2015 | 52 |
| NCT00502671Colorectal Neoplasms · Russian Federation | 4 | Completed | Hoffmann-La Roche | Mar 2012 | 228 |
| NCT00448136Neoplasms · France | 2 | Completed | Hoffmann-La Roche | Nov 2011 | 83 |
| NCT00421824Rectal Neoplasms · Spain | 2 | Completed | Sanofi | Nov 2010 | 108 |
| NCT00411229Stomach Neoplasms · China, Korea, Republic of, Taiwan | 3 | Completed | Sanofi | Nov 2012 | 1,035 |
| NCT00382720Stomach Neoplasms · United States, Belgium, France and more | 2 | Completed | Sanofi | Apr 2010 | 275 |
| NCT00345761Colorectal Neoplasms · Japan | 2 | Completed | Hoffmann-La Roche | Oct 2008 | 64 |
| NCT00263029Rectal Neoplasms | 2 | Completed | Sanofi | Mar 2007 | 18 |
| NCT00207129Neoplasms · United States | 1 | Completed | R-Pharm | Dec 2005 | 25 |
| NCT00174616Rectal Neoplasms · Belgium, France, Germany and more | 2 | Completed | Sanofi | Nov 2007 | 87 |
| NCT00121836Breast Neoplasms · United States | 4 | Completed | Hoffmann-La Roche | Dec 2008 | 109 |
| NCT00118755Colorectal Neoplasms | 2 | Completed | Hoffmann-La Roche | Apr 2009 | 435 |
| NCT00112918Colorectal Neoplasms · United States | 3 | Completed | Hoffmann-La Roche | Jun 2010 | 3,451 |
| NCT00087620Breast Neoplasms · United States | 4 | Terminated | Hoffmann-La Roche | Oct 2004 |
How it is read
Names in the registry
- “Capecitabine”, 62 entries
- “capecitabine”, 16 entries
- “capecitabine [Xeloda]”, 12 entries
- “Utidelone in combination with capecitabine”, 3 entries
- “Capecitabine [Xeloda]”, 3 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 44 studies
- Colorectal Neoplasms, 21 studies
- Stomach Neoplasms, 16 studies
- Pancreatic Neoplasms, 6 studies
- Neoplasms, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.